un-audited Financials Results for the quarter and nine months ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.5 pts less than Nifty Microcap 250 and 10.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Samsrita Labs reported zero revenue from operations for Q3 FY26 (quarter ended 31.12.2025) as well as for the nine months ended December 2025, with the company showing no top-line activity in any period. Standalone loss for the quarter widened sharply to Rs 335.56 lakhs, while the nine-month loss ballooned to Rs 856.72 lakhs compared with just Rs 17.25 lakhs in the corresponding nine months of the previous year. The company wrote off Rs 3.26 crore of intangible assets under development, citing technological obsolescence and no expected future economic benefit, which was the main driver of the surge in 'Other Expenses'. On a consolidated basis, losses were partially offset by share of profits from associates (Kris Biosciences and Qrops Advisory Services). The statutory auditor (MGR & Co) issued an unmodified limited review report but included an 'Emphasis of Matter' paragraph specifically drawing attention to the intangible asset write-off.
This is a negative filing for shareholders — the company is generating no revenue while losses are growing rapidly, and the Rs 3.26 crore intangible asset write-off signals that previously capitalized R&D efforts did not yield usable outcomes. Expect pressure on the stock price and continued concerns about the business's viability.